Pfizer First Quarter 2024 Earnings: Beats Expectations

Pfizer (NYSE:PFE) First Quarter 2024 Results

Key Financial Results

• Revenue: US$14.9b (down 20% from 1Q 2023).
• Net income: US$3.12b (down 44% from 1Q 2023).
• Profit margin: 21% (down from 30% in 1Q 2023).
• EPS: US$0.55 (down from US$0.98 in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pfizer Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 6.9%. Earnings per share (EPS) also surpassed analyst estimates by 61%.

Looking ahead, revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Pfizer that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.